Asunercept is under clinical development by Apogenix and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Asunercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Asunercept overview
APG101 (Apocept) is under development for the treatment of solid tumors including newly diagnosed glioblastoma, myelodysplastic syndrome, amyotrophic lateral sclerosis, cutaneous melanoma, hematological cancer, coronavirus disease 2019 (COVID-19) virus infections with pneumonia and unspecified dermatological disorder. The drug candidate is administered through intravenous route. It is a soluble antibody like recombinant fusion protein combining the extracellular domain of the CD95 receptor (CD95) and the Fc portion of IgG.
The drug candidate was also under development for graft versus host disease (GVHD) and recurrent glioblastoma multiforme.
Apogenix overview
Apogenix, formerly Apogenix, is a pharmaceutical company that develops immuno-oncology medicines and therapeutics for the treatment of oncological and malignant hematological diseases. The company’s pipeline drug candidates under clinical development include Asunercept, a CD95 ligand inhibitor for the treatment of glioblastoma and myelodysplastic syndromes. Apogenix develops the proprietary HERA ligand technology platform for the construction of novel hexavalent receptor agonists for the treatment of cancer. It also conducts preclinical and clinical studies for various tumor indications. The company partners with other pharmaceutical and biotechnology companies and collaborates with academic institutions for the preclinical, clinical development, and commercialization of its proprietary drug candidates. Apogenix is headquartered in Heidelberg, Baden-Wurttemberg, Germany.
For a complete picture of Asunercept’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
